Top Venture Capital Investors in the Psychedelics Industry
Business Insider's Yeji Jesse Lee breaks down the top 11 venture capital investors in terms of dollars deployed into the growing psychedelics industry.
Vine explores novel approaches to conscious health & wellness
Vine is rethinking venture capital for a novel approach to health and wellness.
Ryan Zurrer has been a venture investor and entrepreneur for 16 years. He is an avid biohacker and was an early contributing member to the Quantified Self Movement in the early 2000s. Ryan was a seed investor in some of the best performing venture investments of the 2010s including MakerDAO, Ethereum, Polychain Capital, and a host of other companies.
Ryan launched Polychain’s private investment activities and is considered the creator of the SAFT. Ryan led Polychain Capital’s investment team and was instrumental in delivering Polychain's 2017 returns (in excess of 28X net of fees to LPs).
Ryan has built a reputation for being a hands-on, value-add venture investor with a uniquely global purview. Previously he was CEO of a large Brazilian renewables firm and is responsible for more than 1GW of wind and solar power development globally along with a range of innovations in contracting, financial instruments, and execution of utility-scale renewable energy projects.
Ryan is an honours graduate of the Richard Ivey School of Business where he received the Certificate of Entrepreneurship as well as the Continuing Athletics Scholarship as a member of the Men’s varsity Rugby team.
Ozan Polat is an investor with Vine.
Driven by his intrinsic curiosity, he previously co-founded Dezentrum, a think tank that researches & prototypes positive future scenarios for the digitized society of tomorrow and Trust Square, a technology hub in the heart of Zurich.
The same curiosity and hunger for innovative approaches to our society’s future drove him to Vine Ventures and its novel approach to health & wellness.
Daniel Tarockoff is an investor with Vine interested in the future of mental health, consciousness, and psychedelics.
Prior to Vine, Daniel worked in NYC as a management consultant at PwC Strategy& (formerly Booz & Company), where he worked with clients across the US healthcare ecosystem.
Daniel was an MBA Candidate at UC Berkeley's Haas School of Business before leaving the program to join Vine full-time. He also holds a BBA from the University of Michigan's Ross School of Business.
Zack Lawrence is an investor with Vine. Previously, Zack studied Mathematics (with a focus on cryptography) at Stanford University and also founded and served as CEO of 1protocol, a blockchain startup backed by Andreessen Horowitz. On the side, he is an avid meditater — he spent 6 months living and practicing meditation at a Zen Buddhist Monastery — and volunteers as a grief counselor for children.
Luis Rios is a drug development expert with a Bachelor's in Neurobiology from UC Berkeley and a Ph.D. in Chemical and Systems Biology from Stanford University. With over a decade of experience in molecular sciences, he has published broadly with work in monoamine neuroscience, neuroconnectomics, circadian rhythm, and drug discovery. During his Ph.D., he discovered a novel type of anti-inflammatory, bringing the project from a virtual screen to animal efficacy and industry out-licensing in just nine months. This new type of drug could be a breakthrough in neurodegeneration and sepsis. During his Ph.D., Luis began his career as a biotech consultant for Longitude Capital and is now our Senior Scientific Partner at Vine.
Robbie Bent works with Vine and is co-founder and CEO at Othership, a global community to improve mental health in an accessible way. Othership combines beautiful social spaces that deliver peak experiences and a mobile app that teaches breathwork. Prior to Othership, Robbie was Ecosystem Growth lead at the Ethereum Foundation. He graduated from the Richard Ivey School of Business.